Medical billing and revenue cycle management companies occupy a strange position in healthcare M&A right now. On one hand, demand for what they do has never been higher: providers are drowning in payer requirements, denials work, and prior authorization volume, and a new federal rule is about to reshape how that work flows. On the other hand, artificial intelligence is publicly advertised as the thing that will automate the industry’s core labor away. Both stories are true, and the tension between them is exactly what determines what your billing company is worth in 2026. Sellers who understand which side of that line their business sits on negotiate well. Sellers who do not find out during diligence, which is the most expensive place to learn anything.

Why is 2026 a pivotal year to sell an RCM company?

Three forces are converging. First, the administrative burden that RCM companies exist to absorb keeps growing, and it is now measurable at the national level. The 2025 CAQH Index, the industry’s standard measure of administrative transaction costs, puts the remaining savings opportunity from automating administrative work at 21 billion dollars across the industry. That number is simultaneously the case for RCM services and the case for the technology that could displace parts of them.

Second, federal rules are forcing payers onto faster, more transparent processes, which changes the work RCM companies do on behalf of providers. Third, buyer appetite for tech-enabled services businesses remains strong, but buyers now underwrite RCM companies with a sharper question than they asked five years ago: is this a technology-leveraged operation, or a staffing business with software on top? The answer moves the valuation more than almost anything else, and 2026 is the year the question stopped being polite.

What do the new CMS prior authorization rules mean for RCM demand?

The CMS Interoperability and Prior Authorization final rule (CMS-0057-F, published February 2024) is the regulatory event RCM sellers should be able to explain to a buyer, because its compliance dates land now. Starting in 2026, impacted payers, including Medicare Advantage organizations and Medicaid managed care plans, must make prior authorization decisions within defined timeframes: 72 hours for expedited requests and 7 calendar days for standard requests. They must give providers a specific reason when they deny a prior authorization, and they must publicly report their prior authorization metrics. By January 1, 2027, the same payers must stand up electronic prior authorization APIs so the whole process moves machine to machine.

For a billing company, this cuts two ways. Specific denial reasons and payer-published metrics make denials work more systematic and more winnable, which favors firms with disciplined appeals processes and data. And the API mandate means the prior authorization workflow becomes an integration problem as much as a phone-and-fax problem. RCM companies that are already building toward electronic prior authorization are positioned to absorb the transition for their clients; companies whose prior auth desk is purely manual will watch that revenue get re-priced. A buyer in 2026 will ask which one you are, with dates.

How big is the compliance and accuracy problem RCM solves?

Bigger than most owners bother to quantify in their marketing, which is a missed opportunity in a sale process. CMS’s own Comprehensive Error Rate Testing program estimated the fiscal year 2025 Medicare fee-for-service improper payment rate at 6.55 percent, representing 28.83 billion dollars in improper payments. Most of that is not fraud; it is documentation, coding, and billing that failed to meet requirements. Every point of that number is work a competent RCM operation prevents, and audit exposure a sloppy one creates. A billing company that can show its clients’ denial rates, clean-claim rates, and audit outcomes against benchmarks is selling a compliance asset, not just a back office.

The labor base behind this work is also large and expensive, which is the other half of the buyer math. The Bureau of Labor Statistics’ Occupational Employment and Wage Statistics program counted 194,720 medical records specialists employed nationally as of May 2025, at a mean annual wage of 56,790 dollars, and that occupation is only one slice of the coding and billing workforce. Wherever skilled administrative labor is that costly, the business that organizes it efficiently earns a margin, and the business that automates portions of it earns a better one.

Who buys medical billing and RCM companies in 2026?

• Private equity platforms and their portfolio companies. RCM has been a roll-up category for years because the revenue is recurring, contracts are sticky, and back-office consolidation is straightforward. Platforms buy books of clients, specialty depth, and teams.
• Strategic acquirers. Larger RCM firms and healthcare IT companies buying a specialty (behavioral health billing, therapy billing, anesthesia, labs), a payer niche, or a regional client base they do not have.
• Adjacent services companies. MSOs, credentialing firms, and practice management companies adding billing to an existing client relationship, where your client list is worth more to them than it is to you.
• Individual and partnership buyers. Active at the smaller end, often an operator who knows the industry and wants a book of business with staff in place.

Different buyers price different things. A platform pays for durable EBITDA and integration-ready operations. A strategic may pay a premium for exactly one thing you have, a specialty or a region, and be indifferent to the rest. Running a process that reaches more than one buyer type is how the premium gets found.

What drives an RCM company’s valuation?

• Client concentration. The first number every buyer computes. One client above roughly a fifth of revenue changes the risk profile of the whole business; a top client at 40 or 50 percent dominates the negotiation. Long contracts and multi-year retention history are the counterweight.
• Revenue model. Percentage-of-collections contracts scale with client volume and are the industry standard; flat-fee and per-claim arrangements price differently. Buyers read the contract terms, notice periods, and assignment clauses, so know what your agreements actually say before a buyer does.
• Specialty and payer mix. Deep expertise in a complex specialty is defensible; commodity primary-care billing competes with everyone, including software. Heavy exposure to a single payer type carries the same concentration logic as a big client.
• Technology leverage vs labor arbitrage. The 2026 question. What share of claims flow touches no human? What does your team produce per FTE against industry benchmarks? An offshore-labor cost advantage is real but replicable; workflow automation and clean integrations into client EHRs are harder to copy and priced accordingly.
• Team and key-person risk. If the owner is the senior coder, the sales function, and the client relationship in one person, that is the RCM version of doctor dependence, and it discounts the price the same way.
• Compliance posture. Documented audit results, certified coders, HIPAA program, and clean client audit history. Given the improper payment environment described above, buyers treat compliance records as part of the asset.

As with every vertical we cover, you will not find a valuation multiple quoted here. Billing companies trade on ranges that swing with size, growth, contract quality, and how much of the operation is genuinely automated, and any single number published without your financials in front of us would be exactly the kind of unsourced claim we do not make. The drivers above are what position a specific company inside whatever range the market supports; a confidential valuation is how the number gets named.

How does AI actually change what buyers pay for?

Bluntly: AI moved the premium from headcount to workflow. Five years ago an RCM company’s scale story was how many trained coders and billers it could deploy. Today buyers assume that eligibility checks, claim status inquiries, payment posting, and first-pass coding will be progressively automated, by them if not by you. That reframes the diligence questions. Which functions have you already automated, and what did it do to your cost per claim? Where does your team spend the hours that remain, and is that the judgment-heavy work (complex coding, appeals, payer negotiation, client management) that resists automation longest?

Sellers sometimes fear that AI talk kills the sale. In practice it splits the market. A billing company that can demonstrate automation in production, even modest automation honestly measured, gets underwritten as a platform that will benefit from the technology curve. A company with none gets underwritten as a margin at risk. The 21 billion dollar savings opportunity CAQH measures is going to be captured by someone; the buyer’s whole question is whether your company is positioned to capture it or to lose revenue to it.

How should an RCM owner prepare 12 to 24 months before a sale?

• Fix concentration where you can. Two years of deliberate sales effort diversifying the client base pays for itself several times over at closing. Where a big client cannot be diluted, lock in a longer contract.
• Get the contracts in a folder. Every client agreement, current, signed, with assignment and notice terms you have actually read. Missing or expired agreements stall RCM deals more than any financial issue.
• Measure your own operation. Cost per claim, claims per FTE, first-pass acceptance, denial overturn rate, client retention by cohort. Buyers will build these numbers from your data anyway; sellers who arrive with them control the narrative.
• Pick your automation story and make it true. Deploy automation somewhere measurable and document the before and after. One honest, verified workflow win is worth more in diligence than a slide of intentions.
• Prepare for the 2026-2027 rule wave. Be able to tell a buyer how CMS-0057-F changes your prior authorization work and what you are doing about the API transition. It is the cheapest way to sound like the platform and not the margin at risk.
• Clean the financials. Separate owner expenses, normalize related-party arrangements, and reconcile revenue to client contracts, so the earnings a buyer sees are earnings you can prove.

How do buyers treat offshore operations?

Carefully, and in both directions. A large share of US billing work is performed by offshore teams, most commonly in India and the Philippines, and buyers do not penalize that by itself. What they price is how the offshore operation is built. A wholly owned foreign subsidiary with tenured staff, documented security controls, and clean intercompany accounting reads as durable infrastructure. A loose arrangement with a third-party BPO on a short contract, or an informal team paid through an owner’s side entity, reads as a cost advantage that may not survive the transaction, and buyers discount or restructure around it.

Sellers with offshore teams should be ready for three diligence threads. First, the legal structure: who employs the people, under what entity, and what transfers at closing. Second, security and privacy: where protected health information travels, what the offshore facility’s controls look like, and whether client contracts actually permit the arrangement, because some prohibit offshore processing outright and buyers will read every one. Third, continuity: key-person risk exists offshore too, and a buyer will want the operation to survive the departure of whoever built it. None of these is disqualifying. All of them go better when the answers exist before the question is asked.

How long does an RCM company sale take?

Plan on months, not weeks, and the driver is diligence depth rather than buyer scarcity. RCM diligence reaches into client contracts, HIPAA and security posture, coding compliance samples, employee and contractor classification, and, for offshore operations, the structure and stability of the overseas entity. Client consent or notification requirements in your contracts can add a sensitive final step that has to be choreographed so clients hear the right story at the right time. Add the preparation runway above and the honest planning horizon is one to two years from first conversation to full transition. Owners who begin the year they want to be done give up leverage they never get back.

Where does this leave a billing company owner thinking about selling?

Holding a business that the market genuinely wants, in a window where the rules of the game are being rewritten in ways a prepared seller can turn into a story. Administrative complexity is not going away; the federal government is forcing it onto rails that reward exactly the firms that are organized, measured, and technically current. The gap between what buyers pay for the best-prepared RCM companies and the rest has widened, and preparation, not size, is most of the difference.

Vallexa Advisors represents healthcare business owners through confidential, success-fee sale processes, and revenue cycle management is one of our core verticals. If you own a medical billing or RCM company and want to understand what the current market means for your specific situation, start with our RCM and medical billing company valuation overview or contact us for a confidential conversation. Buyers looking at healthcare services opportunities can see our current inventory, including an established pediatric therapy clinic in northern Illinois and a pediatric ABA practice in Colorado, or join our buyer network to see opportunities first.

Frequently asked questions about selling a medical billing company